Printer Friendly

Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study.

1. Introduction

Organized population-based colorectal cancer (CRC) screening is a critical health intervention due to its proven efficacy for reducing CRC incidence and mortality [1-9] of this now globally prevalent disease [10-12]. This has led to the endorsement of different screening methods by both national and international guidelines [13-17] including guaiac-based fecal occult blood tests, fecal immunochemical tests (FITs), fecal DNA tests, flexible sigmoidoscopy, colonoscopy (CSPY), and computed tomographic colonography, with selection largely based on the performance and cost-effectiveness of the screening strategy [18]. However, arguably the most important parameter is patient preference, which intrinsically impacts screening participation [19-21]. As Canada transitions from opportunistic to programmatic CRC screening, the Canadian Association of Gastroenterology and the Canadian Task Force on Preventative Health have recommended stool-based methods, specifically FIT, to be the preferred method for CRC screening in the average-risk population [13,17].

Although the FIT has a number of advantages over the guaiac-based fecal occult blood test [22-27], one notable feature is the ability to provide quantitative estimates of fecal hemoglobin. This has substantial ramifications on the utility of FIT as the definition of a positive test result can be manipulated, therefore, influencing test performance. This was recently highlighted in a meta-analysis of 19 evaluations reporting the pooled sensitivity and specificity of FIT for cRc which were 79% and 94% [28]. However, with adjustment of the positive FIT cut-off, sensitivity and specificity ranged from 67% to 86% and 91% to 96%, respectively. A limitation of this meta-analysis was that it did not assess FIT performance for detecting high-risk adenomas (HRAs) at varying FIT cut-offs. Other studies that have assessed this relationship between FIT cut-off and HRAs [29-37] either have generally been limited by the number of CSPYs performed among average-risk participants or have evaluated populations including both high-risk and symptomatic participants, thus limiting the applicability of their findings for individuals undergoing CRC screening.

The Canadian Partnership Against Cancer (CPAC) has recommended a FIT-positive predictive value (PPV) for the detection of all adenomas to be [greater than or equal to]50% [38]. The PPV is intrinsically dependent on disease prevalence and studies from North American populations are needed. The aim of this study is to evaluate the performance of FIT in the detection of neoplasia in average-risk participants of the British Columbia Colon Screening Program (BCCSP).

2. Methods

2.1. Data Collection. This study protocol was approved by the British Columbia Cancer Agency (BCCA) Research Ethics Board (ID: H15-01556). Data was obtained from a prospectively collected central database, maintained by the BCCA, with consecutive participants of the BCCSP from Nov2013 to Dec-2014 being considered for inclusion. Participant demographics, FIT value, and CSPY reporting form, which contains details regarding polyp location, size, method of removal, and pathology, are recorded in the BCCSP database.

The following variables were extracted from the BCCSP database: (1) participant baseline demographics; (2) FIT: quantitative results expressed as ng/mL; (3) CSPY: time to CSPY, CSPY quality indicators, and CSPY pathology results. Participants were classified by the highest-risk pathology found on CSPY. HRAs were defined as adenomas or sessile serrated adenomas/polyps [greater than or equal to]10 mm, adenomas [greater than or equal to]20% villous, adenomas with high-grade dysplasia, sessile serrated adenomas/polyps with dysplasia, and traditional serrated adenomas. This definition was modeled after the 2012 Multi-Society Task Force on CRC guidelines for colonoscopy surveillance after screening and polypectomy [39]. Tubular adenomas or sessile serrated adenomas/polyps <10 mm were considered low-risk adenomas (LRAs).

2.2. British Columbia Colon Screening Program. The BCCSP is a province-wide CRC screening program. All asymptomatic men and women aged 50 to 74 years are eligible for enrolment. Potential participants who are up-to-date for CRC screening, have a personal history of CRC, or have received a diagnosis of inflammatory bowel disease are excluded from enrolment.

Potential participants are initially risk-stratified by their primary care provider. High-risk participants, defined as having either a first-degree relative diagnosed with CRC under the age of 60 years, [greater than or equal to]2 first-degree relatives diagnosed with CRC at any age, or a personal history of adenomas, undergo primary CSPY within the program. Participants are otherwise classified as average-risk and receive a single quantitative FIT (NS-Plus, Alfresa Pharma Corporation, Osaka, Japan) with a test cut-off of [greater than or equal to]10 [micro]g hemoglobin/g feces ([greater than or equal to]50 ng hemoglobin/mL of buffer solution). The NS-Plus FIT was chosen in a request for purchase competition by the British Columbia Ministry of Health. The BCCSP did not receive any NS-Plus FIT kits for free, nor did it receive any funding from the company. Instructions for appropriate test completion are provided with each kit. After completion, specimens are returned to a laboratory for processing with results subsequently sent to the BCCSP. FIT is also available outside the BCCSP and participants who were not registered in the program and had an abnormal FIT could be referred to the program for CSPY. All FIT results were developed and interpreted in British Columbia provincial laboratories which are accredited through the College of Physicians and Surgeons of British Columbia Diagnostic Accreditation Program.

Participants with a normal FIT result are recalled by the BCCSP for repeat screening with FIT in 2 years. Participants with an abnormal FIT result are referred to a regional health authority who provides education regarding CSPY and recommendations for bowel cleansing prior to the procedure. CSPY is performed by a local colonoscopist (gastroenterologist, general surgeon, general internist with additional training in CSPY, or general practitioner with additional training in CSPY) selected by hospital administration to participate in the BCCSP who subsequently completes a standardized CSPY reporting form. Specimens taken during CSPY are evaluated by a local pathology laboratory.

2.3. Statistical Analysis. FIT positivity was calculated as the number of FIT-positive participants/the number of total FIT participants. For the purpose of correlating FIT result with findings on CSPY, as a number of BCCSP participants had multiple FITs performed, we correlated FIT result to its pathologic finding for each FIT result. PPV was calculated as the number of specific pathologies (e.g., CRC)/the number of FIT-positive results. PPV was subsequently stratified by FIT cut-off, with the denominator adjusting for the number of FIT-positive results. The percentage of missed pathology was calculated as the number of specific pathologies that would be missed by adjusting the FIT cut-off/the total amount of pathologies detected. Likewise, the percentage of CSPYs saved was calculated as the number of CSPYs that would not be performed by adjusting the FIT cut-off/the total number of CSPYs performed due to a FIT-positive result. The denominators for both the percentage of missed pathology and the percentage of CSPYs saved were based on the FIT cutoff of [greater than or equal to]10 [micro]g/g ([greater than or equal to]50 ng/mL).

Statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Continuous data were expressed as median (Q1-Q3) and categorical data were expressed as frequency (%).

3. Results

3.1. British Columbia Colon Screening Program: Participant Description. Between Nov-2013 and Dec-2014 168,599 participants (median age 61 years; 48.5% male) entered the BCCSP (Figure 1). Of these participants, 32,152 (19.1%) were FIT-positive. When removing participants who entered the BCCSP only once an abnormal FIT was reported, and the FIT positivity rate was 13.6%. Ultimately, 31,464 participants were assessed for CSPY, of which 20,322 (64.6%) underwent CSPY within the BCCSP and 1451 (4.6%) were pending CSPY at time of analysis. Reasons for not advancing to CSPY are detailed in Figure 1.

3.2. Fecal Immunochemical Test: Positivity Rates. FIT positivity data were available for 151,833 BCCSP participants. FIT positivity rate, stratified by age, showed a rising FIT positivity rate as age increased. This pattern was consistent for both men and women. When assessing FIT positivity rate by gender, men had a higher FIT positivity rate, which was consistent across all age groupings.

3.3. Fecal Immunochemical Test: Results and Performance. Of the 20,322 CSPYs performed median time from FIT to CSPY was 94 days (66-131 days). Bowel preparation quality was deemed to be adequate in 97.3% of CSPYs with a cecal intubation rate, adjusted for bowel preparation, of 98.5% for participating colonoscopists.

Pathology results were available for 19,660 positive FITs. Findings, stratified by highest-risk pathology and by FIT value, are described in Table 1. Stratification of pathology findings by various FIT cut-offs is described in Table 2. At the BCCSP FIT cut-off of [micro]10 [micro]g/g ([micro]50 ng/mL) the PPV for CRC, HRAs, all adenomas, and all neoplasia were 2.3%, 20.4%, 52.0%, and 54.2%, respectively.

When comparing a cut-off of [micro]10 [micro]g/g ([micro]50 ng/mL) to [micro]20 [micro]g/g ([micro]100 ng/mL) the PPV for CrC, HRAs, and all neoplasia increased by absolute values of 1.5%, 6.5%, and 5.7%, respectively. The frequency of missed CRCs and HRAs was 61 (13.6%) and 1300 (32.4%), respectively. With increasing FIT cut-off value, the PPV for CRC, HRAs, and all neoplasia increased at a cost of increasing frequency of missed CRCs and HRAs.

4. Discussion

CRC screening is an established health intervention with population-based programs underway worldwide. The United States Preventative Services Task Force, the United States Multi-Society Task Force, and more recently the Canadian Task Force on Preventative Health Care have recommended FIT for CRC screening. The optimal number of specimens per screening round, interval between screening rounds, and cut-off to define a positive test have not been clearly established with variation among published guidelines and screening programs. One source to assess the FIT threshold is the large datasets emerging in association with programmatic screening. Unfortunately, these datasets have limitations. Mostly notably, they are reliant on the PPV to quantify test performance, which is influenced by the population being screened. There is a scarcity of North American data evaluating FIT at various test cut-offs, for CRC as well as HRAs. To our knowledge, this study is the largest Canadian study assessing FIT performance at various test cut-offs and demonstrates that manipulation of the FIT cut-off allows screening programs to balance the PPV for neoplasia, and thus CSPY resources, with the potential for missing neoplastic lesions. These findings inform jurisdictions implementing programmatic CRC screening, specifically in Canada, in selecting a FIT cut-off.

Our study has a number of strengths. Other than evaluating a large North American average-risk population we specifically evaluated the performance of the NS-Plus system for which there is limited published data [40, 41], with one such study advocating for a FIT positivity threshold of 6.3 [micro]g/g among average-risk participants to optimize the sensitivity and specificity of the NS-Plus system [40]. Furthermore, we evaluated a wide range of cut-offs from a positivity threshold of [greater than or equal to]10 [micro]g/g ([greater than or equal to]50 ng/mL). In comparison to previous studies using a [greater than or equal to]10 [micro]g/g cut-off [31,36] (positivity rate: 8.4%-9.6%), our overall positivity rate was higher at 13.6%. This is potentially due to a higher prevalence of colorectal neoplasia in our population or variations in the FIT brand used, which has previously been shown to affect FIT performance [42], although this was not demonstrated in a recent meta-analysis [28]. As anticipated, when comparing our PPV results for CRC and HRAs to previous studies [30, 31, 36, 37], the pattern of increasing PPV for CRC and HRAs with increasing FIT cut-off was reproduced. An unfortunate limitation of the literature is the variability in the definition of HRAs, which has hindered the feasibility for meta-analysis [28]. Inan attempt to increase the applicability of our findings we used a definition for HRAs based on the definition used in the 2012 US Multi-Society Task Force recommendations for surveillance after CSPY [39]. Ultimately, our findings are reassuring that the previously shown correlation between FIT cut-off and PPV is generalizable to a CRC screening program.

Given jurisdictional variation in endoscopic resources, national and international organizations have refrained from providing recommendations for the optimal FIT cut-off. To facilitate policymakers' decision, a number of cost-effectiveness analyses assessing FIT have emerged [43-46], with 2 studies assessing FIT cut-offs across a range of 50 to 100 ng/mL [45] and 50 to 200ng/mL [46]. Both models found that a FIT cut-off of 50 ng/mL was the most cost-effective strategy. In regard to our findings, as the FIT cutoff increased, the PPV for CRC, HRAs, and all neoplasia increased while the number of CSPYs for that screening round decreased. However, this was at the cost of missed neoplastic lesions. It is important to note that our study evaluated a single screening cycle. With that in mind, the number of CSPYs saved is misleading and does not account for participants with a false negative FIT who may require a CSPY during subsequent screening rounds. Moreover, the frequency of missed neoplasia in our study represents those lesions with a corresponding FIT value of [greater than or equal to]10 [micro]g/g ([greater than or equal to]50ng/mL) and does not include neoplasia in participants with a FIT value of <10 [micro]g/g (<50ng/mL) who did not undergo CSPY. Given these limitations, evaluation of subsequent screening cycles to provide a more accurate estimate regarding the balance between optimization of CSPY resources and FIT performance is needed.

In addition to the limitations discussed above, we were unable to calculate detection rates of CRC for the entire screening population as a proportion of patients underwent FIT outside of the BCCSP. Of these participants, those with a negative FIT would not have been registered and those with a positive FIT may have undergone CSPY outside the BCCSP or may have been referred for CSPY within the program. Therefore, all calculations related to positivity rate are limited to those participants who underwent FIT within the BCCSP. Moreover, to facilitate analyses, we classified findings based on the highest-risk pathology found on CSPY. This potentially obscured the evaluation of FIT performance for lower-risk pathology. Lastly, demographic data such as ethnicity and level of education as well as CRC stage at time of diagnosis were not available for analysis, limiting the generalizability of our study.

5. Conclusions

In conclusion, this is the largest Canadian study assessing FIT performance among average-risk participants across various FIT cut-offs. Our findings support that previously established correlations between FIT value and CSPY findings hold true in a "real-world" setting. The current BCCSP FIT cut-off generates a PPV for all adenomas that meets the recommended Canadian benchmark and the program will continue to utilize this FIT threshold with the goal of optimizing both patient outcomes and resource utilization.

Abbreviations
BCCA:    British Columbia Cancer Agency
BCCSP:   British Columbia Colon Screening Program
CPAC:    Canadian Partnership Against Cancer
CRC:     Colorectal cancer
CSPY:    Colonoscopy
FIT:     Fecal immunochemical test
HRA:     High-risk adenoma
LRA:     Low-risk adenoma
MLRA:    Multiple low-risk adenomas
N:       Number
PPV:     Positive predictive value.


http://dx.doi.org/10.1155/2016/4650471

Disclosure

An earlier version of this work was presented as an abstract at Canadian Digestive Diseases Week (CDDW) 2016 and Digestive Disease Week (DDW) 2016.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] O. Kronborg, C. Fenger, J. Olsen, O. D. Jorgensen, and O. Sondergaard, "Randomised study of screening for colorectal cancer with faecal-occult-blood test," The Lancet, vol. 348, no. 9040, pp. 1467-1471, 1996.

[2] J. D. Hardcastle, J. O. Chamberlain, M. H. E. Robinson et al., "Randomised controlled trial of faecal-occult-blood screening for colorectal cancer," The Lancet, vol. 348, no. 9040, pp. 1472-1477, 1996.

[3] J. S. Mandel, T. R. Church, J. H. Bond et al., "The effect of fecal occult-blood screening on the incidence of colorectal cancer," The New England Journal of Medicine, vol. 343, no. 22, pp. 1603-1607, 2000.

[4] O. D. Jorgensen, O. Kronborg, and C. Fenger, "A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds," Gut, vol. 50, no. 1, pp. 29-32, 2002.

[5] J. Faivre, V. Dancourt, C. Lejeune et al., "Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study," Gastroenterology, vol. 126, no. 7, pp. 1674-1680, 2004.

[6] W. S. Atkin, R. Edwards, I. Kralj-Hans et al., "Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial," The Lancet, vol. 375, no. 9726, pp. 1624-1633, 2010.

[7] N. Segnan, P. Armaroli, L. Bonelli et al., "Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial--SCORE," Journal of the National Cancer Institute, vol. 103, no. 17, pp. 1310-1322, 2011.

[8] R. E. Schoen, P. F. Pinsky, J. L. Weissfeld et al., "Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy," The New England Journal of Medicine, vol. 366, no. 25, pp. 2345-2357, 2012.

[9] A. Shaukat, S. J. Mongin, M. S. Geisser et al., "Long-term mortality after screening for colorectal cancer," The New England Journal of Medicine, vol. 369, no. 12, pp. 1106-1114, 2013.

[10] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.

[11] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.

[12] M. M. Center, A. Jemal, R. A. Smith, and E. Ward, "Worldwide variations in colorectal cancer," CA: A Cancer Journal for Clinicians, vol. 59, no. 6, pp. 366-378, 2009.

[13] D. J. Leddin, R. Enns, R. Hilsden et al., "Canadian Association of Gastroenterology position statement on screening individuals at average risk for developing colorectal cancer: 2010," Canadian Journal of Gastroenterology, vol. 24, no. 12, pp. 705-714, 2010.

[14] U.S. Preventive Services Task Force, "Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement," Annals of Internal Medicine, vol. 149, no. 9, pp. 627-637, 2008.

[15] O. G. Dominic, T. McGarrity, M. Dignan, and E. J. Lengerich, "American College of Gastroenterology Guidelines for colorectal cancer screening 2008," The American Journal of Gastroenterology, vol. 104, no. 10, pp. 2626-2627, 2009.

[16] B. Levin, D. A. Lieberman, B. McFarland et al., "Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer and the American College of Radiology," Gastroenterology, vol. 134, no. 5, pp. 1570-1595, 2008.

[17] Canadian Task Force on Preventive Health Care, "Recommendations on screening for colorectal cancer in primary care," Canadian Medical Association Journal, vol. 188, no. 5, pp. 340-348, 2016.

[18] J. E. Allison, C. G. Fraser, S. P. Halloran, and G. P. Young, "Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT)," Gut and Liver, vol. 8, no. 2, pp. 117-130, 2014.

[19] S. R. Cole and G. P. Young, "Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer," Medical Journal of Australia, vol. 175, no. 4, pp. 195-198, 2001.

[20] S. R. Cole, G. P. Young, A. Esterman, B. Cadd, and J. Morcom, "A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer," Journal of Medical Screening, vol. 10, no. 3, pp. 117-122, 2003.

[21] G. Vart, R. Banzi, and S. Minozzi, "Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis," Preventive Medicine, vol. 55, no. 2, pp. 87-92, 2012.

[22] M. H. E. Robinson, C. G. Marks, P. A. Farrands, W. M. Thomas, and J. D. Hardcastle, "Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests," British Journal of Surgery, vol. 81, no. 3, pp. 448-451, 1994.

[23] P. Rozen, J. Knaani, and N. Papo, "Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia," European Journal of Cancer Prevention, vol. 4, no. 6, pp. 475-481, 1995.

[24] J. E. Allison, I. S. Tekawa, L. J. Ransom, and A. L. Adrain, "A comparison of fecal occult-blood tests for colorectal-cancer screening," The New England Journal of Medicine, vol. 334, no. 3, pp. 155-159, 1996.

[25] N. petrelli, A. M. Michalek, A. Freedman, M. Baroni, I. Mink, and M. Rodriguez-Bigas, "Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program," Surgical Oncology, vol. 3, no. 1, pp. 27-36, 1994.

[26] D. I. Park, S. Ryu, Y.-H. Kim et al., "Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening," The American Journal of Gastroenterology, vol. 105, no. 9, pp. 2017-2025, 2010.

[27] L. G. van Rossum, A. F. van Rijn, R. J. Laheij et al., "Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population," Gastroenterology, vol. 135, no. 1, pp. 82-90, 2008.

[28] J. K. Lee, E. G. Liles, S. Bent, T. R. Levin, and D. A. Corley, "Accuracy of fecal immunochemical tests for colorectal cancer," Annals of Internal Medicine, vol. 160, no. 3, pp. 171-181, 2014.

[29] N. H. Kim, M. J. Kwon, H. Y. Kim et al., "Fecal hemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia," Digestive and Liver Disease, vol. 48, no. 6, pp. 667-672, 2016.

[30] C. Alvarez-Urturi, M. Andreu, C. Hernandez et al., "Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening," Digestive and Liver Disease, vol. 48, no. 5, pp. 542-551, 2016.

[31] A. Kapidzic, M. P. van der Meulen, L. Hol et al., "Gender differences in fecal immunochemical test performance for early detection of colorectal neoplasia," Clinical Gastroenterology and Hepatology, vol. 13, no. 8, pp. 1464.e4-1471.e4, 2015.

[32] L. G. M. Van Rossum, A. F. Van Rijn, R. J. F. Laheij et al., "Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme," British Journal of Cancer, vol. 101, no. 8, pp. 1274-1281, 2009.

[33] Z. Levi, P. Rozen, R. Hazazi et al., "A quantitative immunochemical fecal occult blood test for colorectal neoplasia," Annals of Internal Medicine, vol. 146, no. 4, pp. 244-255, 2007.

[34] P. Rozen, D. Comaneshter, Z. Levi et al., "Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use," Cancer, vol. 116, no. 9, pp. 2115-2125, 2010.

[35] S. T. Van Turenhout, F. A. Oort, R. W. Van Der Hulst et al., "Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?" BMC Gastroenterology, vol. 14, article 217, 2014.

[36] T. R. De Wijkerslooth, E. M. Stoop, P. M. Bossuyt et al., "Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia," The American Journal of Gastroenterology, vol. 107, no. 10, pp. 1570-1578, 2012.

[37] J. M. Auge, M. Pellise, J. M. Escudero et al., "Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program," Gastroenterology, vol. 147, no. 3, pp. 628.e1-636.e1, 2014.

[38] Canadian Partnership Against Cancer, Quality Determinants and Indicators for Measuring Colorectal Cancer Screening Program Performance in Canada, The Partnership, Toronto, Canada, 2012.

[39] D. A. Lieberman, D. K. Rex, S. J. Winawer, F. M. Giardiello, D. A. Johnson, and T. R. Levin, "Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the us multi-society task force on colorectal cancer," Gastroenterology, vol. 143, no. 3, pp. 844-857, 2012.

[40] Y.-H. Lee, M. Hur, H. Kim et al., "Optimal cut-off concentration for a faecal immunochemical test for haemoglobin by Hemo Techt NS-Plus C15 system for the colorectal cancer screening," Clinical Chemistry and Laboratory Medicine, vol. 53, no. 3, pp. e69-e71, 2015.

[41] E. Randell, M. Kennell, A. Taher et al., "Evaluation of Hemo Techt NS-Plus system for use in a province-wide colorectal cancer screening program," Clinical Biochemistry, vol. 46, no. 4-5, pp. 365-368, 2013.

[42] T.-H. Chiang, S.-L. Chuang, S. L.-S. Chen et al., "Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program," Gastroenterology, vol. 147, no. 6, pp. 1317-1326, 2014.

[43] J. J. Telford, A. R. Levy, J. C. Sambrook, D. Zou, and R. A. Enns, "The cost-effectiveness of screening for colorectal cancer," Canadian Medical Association Journal, vol. 182, no. 12, pp. 1307-1313, 2010.

[44] S. J. Heitman, R. J. Hilsden, F. Au, S. Dowden, and B. J. Manns, "Colorectal cancer screening for average-risk north americans: an economic evaluation," PLoS Medicine, vol. 7, no. 11, Article ID e1000370, 2010.

[45] A. J. Coldman, N. Phillips, J. Brisson et al., "Using the cancer risk management model to evaluate colorectal cancer screening options for Canada," Current Oncology, vol. 22, no. 2, pp. e41e50, 2015.

[46] J. A. Wilschut, L. Hol, E. Dekker et al., "Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening," Gastroenterology, vol. 141, no. 5, pp. 1648-1655, 2011.

Neal Shahidi, (1) Laura Gentile, (2) Lovedeep Gondara, (2) Jeremy Hamm, (2) Colleen E. McGahan, (2) Robert Enns, (1) and Jennifer Telford (1,2)

(1) St. Paul's Hospital, Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

(2) British Columbia Cancer Agency, Vancouver, BC, Canada

Correspondence should be addressed to Jennifer Telford; jtelford@telus.net

Received 18 August 2016; Revised 6 November 2016; Accepted 9 November 2016

Academic Editor: Geoffrey Williams

Caption: Figure 1: British Columbia Colon Screening Program Flow Diagram. CRC, colorectal cancer; CSPY, colonoscopy; FIT, fecal immunochemical test; HRA, high-risk adenoma; LRA, low-risk adenoma; MLRA, multiple low-risk adenomas.
Table 1: Pathology results by fecal immunochemical test value.

               10-14.9 [micro]g/g   15-19.9 [micro]g/g
                 (50-74 ng/mL)        (75-99 ng/mL)
                     (N/%)                (N/%)

CRC                 40 (0.6)             21 (0.7)
HRA                836 (12.6)           464 (15.8)
MLRA               401 (6.0)            188 (6.4)
LRA               1857 (28.0)           813 (27.7)
No neoplasia      3507 (52.8)          1444 (49.3)
Total                 6641                 2930

               20-39.9 [micro]g/g   40-99.9 [micro]g/g
                (100-199 ng/mL)      (200-499 ng/mL)
                     (N/%)                (N/%)

CRC                 44 (1.1)            102 (3.2)
HRA                801 (19.8)           802 (25.4)
MLRA               263 (6.5)            189 (6.0)
LRA               1112 (27.5)           773 (24.5)
No neoplasia      1824 (45.1)          1292 (40.9)
Total                 4044                 3158

                 [greater than or     Total (N/%)
                   equal to]100
               [micro]g/g ([greater
               than or equal to]500
                   ng/mL) (N/%)

CRC                 242 (8.4)          449 (2.3)
HRA                1109 (38.4)        4012 (20.4)
MLRA                132 (4.6)         1173 (6.0)
LRA                 474 (16.4)        5029 (25.6)
No neoplasia        930 (32.2)        8997 (45.8)
Total                  2887              19660

CRC, colorectal cancer; HRA, high-risk adenoma;
LRA, low-risk adenoma; MLRA, multiple low-risk adenomas.

Table 2: Fecal immunochemical test performance by test cut-off.

                  [greater than or       [greater than or
                    equal to]10            equal to]15
                [micro]g/g ([greater   [micro]g/g ([greater
                than or equal to]50    than or equal to]75
                    ng/mL) (N/%)           ng/mL) (N/%)

CRC                  449 (2.3)              409 (3.1)
Missed CRC               --                  40 (8.9)
HRA                 4012 (20.4)            3176 (24.4)
Missed HRA               --                 836 (20.8)
MLRA                 1173 (6.0)             772 (5.9)
LRA                 5029 (25.6)            3172 (24.4)
All neoplasia       10663 (54.2)           7529 (57.8)
CSPY saved               --                6641 (33.8)
Total results          19660                  13019

                  [greater than or       [greater than or
                    equal to]20            equal to]40
                [micro]g/g ([greater   [micro]g/g ([greater
                than or equal to]100   than or equal to]200
                    ng/mL) (N/%)           ng/mL) (N/%)

CRC                  388 (3.8)              344 (5.7)
Missed CRC           61 (13.6)              105 (23.4)
HRA                 2712 (26.9)            1911 (31.6)
Missed HRA          1300 (32.4)            2101 (52.4)
MLRA                 584 (5.8)              321 (5.3)
LRA                 2359 (23.4)            1247 (20.6)
All neoplasia       6043 (59.9)            3823 (63.2)
CSPY saved          9571 (48.7)            13615 (69.3)
Total results          10089                   6045

                  [greater than or
                    equal to]100
                [micro]g/g ([greater
                than or equal to]500
                    ng/mL) (N/%)

CRC                  242 (8.4)
Missed CRC           207 (46.1)
HRA                 1109 (38.4)
Missed HRA          2903 (72.4)
MLRA                 132 (4.6)
LRA                  474 (16.4)
All neoplasia       1957 (67.8)
CSPY saved          16773 (85.3)
Total results           2887

CRC, colorectal cancer; CSPY, colonoscopy; HRA, high-risk
adenoma; LRA, low-risk adenoma; MLRA, multiple
low-risk adenomas.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Shahidi, Neal; Gentile, Laura; Gondara, Lovedeep; Hamm, Jeremy; McGahan, Colleen E.; Enns, Robert; T
Publication:Canadian Journal of Gastroenterology and Hepatology
Article Type:Report
Date:Jan 1, 2017
Words:4808
Previous Article:Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial.
Next Article:Aseptic Abscesses and Inflammatory Bowel Disease: Two Cases and Review of Literature.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters